NCT00417885View on ClinicalTrials.gov

A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Breast Neoplasms
Interventions
DRUG

exemestane

25 mg, oral, daily dosing

DRUG

sunitinib malate

37.5 mg, oral, continuous dosing, daily

Trial Locations (3)

30322

Pfizer Investigational Site, Atlanta

H3G 1A4

Pfizer Investigational Site, Montreal

H3G 1L5

Pfizer Investigational Site, Montreal

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00417885 - A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer | Biotech Hunter | Biotech Hunter